ReviewPharmaceutics2026
Advances in Polymer Micelles for Cancer Therapy: From Conventional to Smart Delivery Systems.
Review in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Understanding DMG: current treatment options and prospective solutions using nanoparticles.Drug delivery and translational research · 2026Review
- PEG-b-PCL Micelles as Nanocarriers for Poorly Soluble Benzimidazoles: A Comparative Study of Albendazole and Fenbendazole.Molecules (Basel, Switzerland) · 2026Article
- Formulation Progress, Challenges, and Perspectives of Anti-Inflammatory Natural Products.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Polymeric micelles have become a versatile and clinically significant class of nanocarriers for cancer therapy. They effectively solubilize poorly water-soluble anticancer drugs, extend their circulation in the bloodstream, and promote accumulation in tumors. Early studies focused on conventional PEG-based polymeric micelles that utilize passive targeting based on the enhanced permeability and retention (EPR) effect, with several of these advancing to clinical trials. Active targeting strategies using modified polymer micelles with various targeting ligands have been introduced to enhance cellular uptake and improve tumor specificity. Recently, the field has shifted toward smart polymer micelles that can respond to both internal (endogenous) and external (exogenous) stimuli. These stimuli-responsive systems enable controlled drug release, enhance delivery inside cells, and improve therapeutic effectiveness, all while reducing systemic toxicity. This review summarizes recent advancements in polymer design, drug-loading techniques, preparation methods, and targeting strategies for polymeric micelles, highlighting both preclinical progress and systems that have reached clinical stages. The transition from conventional to smart polymer micelles is a significant advancement toward achieving more precise, effective, and personalized cancer nanomedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.